Nuvation Bio Inc.
NYSE:NUVB
2.68 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Nuvation Bio Inc. |
Symbool | NUVB |
Munteenheid | USD |
Prijs | 2.68 |
Beurswaarde | 901,999,560 |
Dividendpercentage | 0% |
52-weken bereik | 1.43 - 4.16 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David T. Hung M.D. |
Website | https://www.nuvationbio.com |
An error occurred while fetching data.
Over Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)